Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study
Abstract Background The World Health Organization (WHO) has identified carbapenem-resistant Pseudomonas aeruginosa (CRPA) as one of the three critical priority pathogens. There is scarce literature evaluating the treatment outcomes in patients with CRPA infections treated with traditional non-carbap...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-024-10365-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850101979268775936 |
|---|---|
| author | Namareq F. Aldardeer Hatun M. Labban Raghad T. Alhuthil Seham H. Aljahdali Moataz H. Alharbi Riham A. Alharbi Mohammed I. Al Musawa Abdulrahman A. Almalki Thamer A. Almangour |
| author_facet | Namareq F. Aldardeer Hatun M. Labban Raghad T. Alhuthil Seham H. Aljahdali Moataz H. Alharbi Riham A. Alharbi Mohammed I. Al Musawa Abdulrahman A. Almalki Thamer A. Almangour |
| author_sort | Namareq F. Aldardeer |
| collection | DOAJ |
| description | Abstract Background The World Health Organization (WHO) has identified carbapenem-resistant Pseudomonas aeruginosa (CRPA) as one of the three critical priority pathogens. There is scarce literature evaluating the treatment outcomes in patients with CRPA infections treated with traditional non-carbapenem β-lactam (NCBL) agents. Thus, this study aims to assess the effectiveness of traditional NCBL compared to novel β-lactam agents (NVL) for treating non-carbapenem β-lactam -susceptible CRPA. Methods A single-center retrospective cohort study was conducted between January 2016 and December 2022. The study included adult patients 18 years and older with infection due to CRPA who were treated based on microbiology sensitivity with traditional NCBL or NVL for more than 48 h. The primary outcome was 30-day mortality. Results 124 patients were included: 98 (79%) in the NCBL group and 26 (20.9%) in the NVL group. 78 (62.9%) patients were male. The median (interquartile range (IQR)) age of included patients was 64 (45, 77) years. A total of 84 (67.7%) patients were critically ill, with an overall median (IQR) APACHE II score of 18 (13.5, 23). The rates of 30-day mortality in NCBL and NVL groups were 41 (41.8%) and 12 (46.2%), respectively; P = 0.692. Conclusion In patients with CRPA infections susceptible to traditional NCBL, there was no statisticallly significant difference in 30-day mortality among patients who were treated with traditional NCBL compared with NVL. Further studies with larger sample sizes are needed to confirm these findings. |
| format | Article |
| id | doaj-art-d1e89d550ccd46dda2ea9490310bfa9c |
| institution | DOAJ |
| issn | 1471-2334 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj-art-d1e89d550ccd46dda2ea9490310bfa9c2025-08-20T02:39:51ZengBMCBMC Infectious Diseases1471-23342024-12-012411910.1186/s12879-024-10365-5Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort studyNamareq F. Aldardeer0Hatun M. Labban1Raghad T. Alhuthil2Seham H. Aljahdali3Moataz H. Alharbi4Riham A. Alharbi5Mohammed I. Al Musawa6Abdulrahman A. Almalki7Thamer A. Almangour8Critical Care Clinical Pharmacy Consultant, Medical and Clinical Affairs Department, King Faisal Specialist Hospital and Research CenterPediatric Antimicrobial Stewardship Clinical Pharmacist , King Saud Medical CityDepartment of Pediatrics, King Faisal Specialist Hospital and Research CenterPharmacist, Saudi German Hospital Saudi German HospitalPharmacy Department, King Faisal Specialist Hospital and Research CenterAnti-Infective Research Laboratory, Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State UniversityClinical Pharmacist, Medical and Critical Care Pharmacy, King Faisal Specialist Hospital and Research CenterClinical Pharmacy Department, College of Pharmacy, King Saud UniversityAbstract Background The World Health Organization (WHO) has identified carbapenem-resistant Pseudomonas aeruginosa (CRPA) as one of the three critical priority pathogens. There is scarce literature evaluating the treatment outcomes in patients with CRPA infections treated with traditional non-carbapenem β-lactam (NCBL) agents. Thus, this study aims to assess the effectiveness of traditional NCBL compared to novel β-lactam agents (NVL) for treating non-carbapenem β-lactam -susceptible CRPA. Methods A single-center retrospective cohort study was conducted between January 2016 and December 2022. The study included adult patients 18 years and older with infection due to CRPA who were treated based on microbiology sensitivity with traditional NCBL or NVL for more than 48 h. The primary outcome was 30-day mortality. Results 124 patients were included: 98 (79%) in the NCBL group and 26 (20.9%) in the NVL group. 78 (62.9%) patients were male. The median (interquartile range (IQR)) age of included patients was 64 (45, 77) years. A total of 84 (67.7%) patients were critically ill, with an overall median (IQR) APACHE II score of 18 (13.5, 23). The rates of 30-day mortality in NCBL and NVL groups were 41 (41.8%) and 12 (46.2%), respectively; P = 0.692. Conclusion In patients with CRPA infections susceptible to traditional NCBL, there was no statisticallly significant difference in 30-day mortality among patients who were treated with traditional NCBL compared with NVL. Further studies with larger sample sizes are needed to confirm these findings.https://doi.org/10.1186/s12879-024-10365-5CarbapenemResistancePseudomonas aeruginosaCephalosporinsPiperacillin/Tazobactam |
| spellingShingle | Namareq F. Aldardeer Hatun M. Labban Raghad T. Alhuthil Seham H. Aljahdali Moataz H. Alharbi Riham A. Alharbi Mohammed I. Al Musawa Abdulrahman A. Almalki Thamer A. Almangour Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study BMC Infectious Diseases Carbapenem Resistance Pseudomonas aeruginosa Cephalosporins Piperacillin/Tazobactam |
| title | Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study |
| title_full | Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study |
| title_fullStr | Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study |
| title_full_unstemmed | Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study |
| title_short | Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study |
| title_sort | effectiveness of traditional non carbapenem β lactams vs novel β lactams for the treatment of carbapenem resistant pseudomonas aeruginosa a retrospective cohort study |
| topic | Carbapenem Resistance Pseudomonas aeruginosa Cephalosporins Piperacillin/Tazobactam |
| url | https://doi.org/10.1186/s12879-024-10365-5 |
| work_keys_str_mv | AT namareqfaldardeer effectivenessoftraditionalnoncarbapenemblactamsvsnovelblactamsforthetreatmentofcarbapenemresistantpseudomonasaeruginosaaretrospectivecohortstudy AT hatunmlabban effectivenessoftraditionalnoncarbapenemblactamsvsnovelblactamsforthetreatmentofcarbapenemresistantpseudomonasaeruginosaaretrospectivecohortstudy AT raghadtalhuthil effectivenessoftraditionalnoncarbapenemblactamsvsnovelblactamsforthetreatmentofcarbapenemresistantpseudomonasaeruginosaaretrospectivecohortstudy AT sehamhaljahdali effectivenessoftraditionalnoncarbapenemblactamsvsnovelblactamsforthetreatmentofcarbapenemresistantpseudomonasaeruginosaaretrospectivecohortstudy AT moatazhalharbi effectivenessoftraditionalnoncarbapenemblactamsvsnovelblactamsforthetreatmentofcarbapenemresistantpseudomonasaeruginosaaretrospectivecohortstudy AT rihamaalharbi effectivenessoftraditionalnoncarbapenemblactamsvsnovelblactamsforthetreatmentofcarbapenemresistantpseudomonasaeruginosaaretrospectivecohortstudy AT mohammedialmusawa effectivenessoftraditionalnoncarbapenemblactamsvsnovelblactamsforthetreatmentofcarbapenemresistantpseudomonasaeruginosaaretrospectivecohortstudy AT abdulrahmanaalmalki effectivenessoftraditionalnoncarbapenemblactamsvsnovelblactamsforthetreatmentofcarbapenemresistantpseudomonasaeruginosaaretrospectivecohortstudy AT thameraalmangour effectivenessoftraditionalnoncarbapenemblactamsvsnovelblactamsforthetreatmentofcarbapenemresistantpseudomonasaeruginosaaretrospectivecohortstudy |